Department of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Children's Neurosciences, Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, London, UK.
Ann Clin Transl Neurol. 2024 Nov;11(11):3025-3030. doi: 10.1002/acn3.52198. Epub 2024 Oct 2.
It is unknown if cognition is impaired before clinical onset of paediatric acquired demyelinating syndromes. We conducted a matched cohort study using prospectively collected educational data in multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) patients (n = 60) and controls (pooled n = 449,553). Academic performance at ages 10-11 was impaired in MOGAD (-1.27 adjusted z-score [95% CI: -1.81 to -0.73], P < 0.001) and preclinical MS (-0.40 [-0.80 to -0.0003], P = 0.0498). Moderate/high-efficacy MS treatment was associated with better final academic performance (0.92 [0.28-1.57], P = 0.005). After clinical onset MS patients missed 8.7% of school (controls 2.9%, P < 0.001) and MOGAD patients 11.9% (controls 2.0%, P < 0.001).
尚不清楚儿科获得性脱髓鞘综合征的临床发病前是否存在认知障碍。我们进行了一项匹配队列研究，使用多发性硬化症（MS）和髓鞘少突胶质细胞糖蛋白抗体病（MOGAD）患者（n=60）和对照组（合并 n=449553）前瞻性收集的教育数据。MOGAD（-1.27 调整后的 z 评分 [95%CI：-1.81 至-0.73]，P<0.001）和临床前 MS（-0.40 [-0.80 至-0.0003]，P=0.0498）患者在 10-11 岁时的学业成绩受损。中/高疗效 MS 治疗与更好的最终学业成绩相关（0.92 [0.28-1.57]，P=0.005）。在临床发病后，MS 患者缺课 8.7%（对照组为 2.9%，P<0.001），MOGAD 患者缺课 11.9%（对照组为 2.0%，P<0.001）。
